Lifeboat Foundation

WASHINGTON (Reuters) — The U.S. Food and Drug Administration (FDA) on Friday approved Thermo Fisher Scientific Inc’s coronavirus test, which would allow the firm to increase capacity to 1.4 million tests a week, a Trump administration official said.

“This will dramatically increase our ability to test people for the virus,” the official said. It was not immediately clear if capacity referred to test kit production or processing of tests performed on individual patients.

The move comes as the Trump administration struggles to meet demand for testing. The FDA has already approved emergency authorization for a faster coronavirus test made by Swiss diagnostics maker Roche.

Along with academic research departments around the world, private sector medical technology companies are getting in on the action, seeking ways to increase longevity and health span.

China and South Korea used smartphone apps to monitor people with the disease. But Americans have different views of privacy and data collection.

Coronavirus’s economic danger is exponentially greater than its health risks to the public. If the virus does directly affect your life, it is most likely to be through stopping you going to work, forcing your employer to make you redundant, or bankrupting your business.

The trillions of dollars wiped from financial markets this week will be just the beginning, if our governments do not step in. And if President Trump continues to stumble in his handling of the situation, it may well affect his chances of re-election. Joe Biden in particular has identified Covid-19 as a weakness for Trump, promising “steady, reassuring” leadership during America’s hour of need.

Continue reading “Coronavirus will bankrupt more people than it kills — and that’s the real global emergency” »

Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.

Scientific Reports volume 10, Article number: 4642 (2020) Cite this article.

Two other international teams are planning Mars launches in July. NASA plans to deploy a rover named Perseverance, and the United Arab Emirates will send a probe called Hope. The European and Russian space agencies were planning to send a probe to Mars this year, but announced on Thursday that the launch will be delayed by two years so they can finish important tests, and partly because of the coronavirus pandemic.

China’s first journey to Mars is one of the most anticipated space missions of the year. But with parts of the country in some form of lockdown because of the coronavirus, the mission teams have had to find creative ways to continue their work.

Researchers involved in the mission remain tight-lipped about its key aspects, but several reports from Chinese state media say that the outbreak will not affect the July launch — the only window for another two years.

Continue reading “How China is planning to go to Mars amid the coronavirus outbreak” »

Scientists who study the biology of Aging agreed that we would someday be able to slow down the aging process substantially.

Dr. Aubrey de Grey, Chief Science Officer at SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics believes that the critical biomedical technology required to eliminate aging derived debilitation and death is now within reach.

In his book “Ending Aging” he and his research assistant Michael Rae described the details of this biotechnology. They explained that the Aging of the human body, just like the Aging of manmade machines, results from an accumulation of various types of damage. As with manmade machines, this damage can periodically be repaired, leading to the indefinite extension of the machines fully functional lifetime just as is routinely done with classic cars.

Ren Zhiqiang appears to be the latest government critic silenced by the Communist Party as it cracks down on dissent over the epidemic.